In addition, we consider that Epimedium and ICT might sensitize the cancers to anti-PD-1/PD-L1 or anti-CTLA4 via increasing the infiltration of CD8+ T cells, since immune checkpoint blockade therapies often fail in the patients with poor T cell infiltration. The gene discussed is CD8A; the disease is cancer.